search
Back to results

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Primary Purpose

Atopic Dermatitis Eczema

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
ARQ-151 Active
ARQ-151 Vehicle
Sponsored by
Arcutis Biotherapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atopic Dermatitis Eczema

Eligibility Criteria

2 Years - 5 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Informed consent by parent(s) or legal guardian as required by local laws.
  2. Males and females, ages 2 to 5 years old at time of signing Informed Consent (Screening) and at Baseline (Day 1).
  3. Diagnosed with atopic dermatitis for at least 6 weeks, as determined by the Investigator. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening.
  4. In good health as judged by the Investigator.
  5. Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion Criteria:

  1. Subjects with any serious medical condition or clinically significant abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator
  2. Has unstable AD or any consistent requirement for high potency topical steroids.
  3. Subjects who are unwilling to refrain from prolonged sun exposure for 4 weeks prior to Baseline/Day 1 and during the study.
  4. Previous treatment with ARQ-151.
  5. Parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language(s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
  6. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled (in other studies of ARQ-151) subjects living in the same house.

Sites / Locations

  • Arcutis Clinical Site 56
  • Arcutis Clinical Site 14
  • Arcutis Clinical Site 69
  • Arcutis Clinical Site 68
  • Arcutis Clinical Site 26
  • Arcutis Clinical Site 50
  • Arcutis Clinical Site 59
  • Arcutis Clinical Site 71
  • Arcutis Clinical Site 09
  • Arcutis Clinical Site 45
  • Arcutis Clinical Site 30
  • Arcutis Clinical Site 70
  • Arcutis Clinical Site 48
  • Arcutis Clinical Site 33
  • Arcutis Clinical Site 12
  • Arcutis Clinical Site 11
  • Arcutis Clinical Site 28
  • Arcutis Clinical Site 10
  • Arcutis Clinical Site 79
  • Arcutis Clinical Site 43
  • Arcutis Clinical Site 35
  • Arcutis Clinical Site 75
  • Arcutis Clinical Site 20
  • Arcutis Clinical Site 82
  • Arcutis Clinical Site 60
  • Arcutis Clinical Site 07
  • Arcutis Clinical Site 42
  • Arcutis Clinical Site 21
  • Arcutis Clinical Site 57
  • Arcutis Clinical Site 22
  • Arcutis Clinical Site 46
  • Arcutis Clinical Site 84
  • Arcutis Clinical Site 34
  • Arcutis Clinical Site 51
  • Arcutis Clinical Site 40
  • Arcutis Clinical Site 77
  • Arcutis Clinical Site 13
  • Arcutis Clinical Site 15
  • Arcutis Clinical Site 53
  • Arcutis Clinical Site 41
  • Arcutis Clinical Site 36
  • Arcutis Clinical Site 72
  • Arcutis Clinical Site 05
  • Arcutis Clinical Site 47
  • Arcutis Clinical Site 16
  • Arcutis Clinical Site 55
  • Arcutis Clinical Site 54
  • Arcutis Clinical Site 44
  • Arcutis Clinical Site 32
  • Arcutis Clinical Site 58
  • Arcutis Clinical Site 81
  • Arcutis Clinical Site 01
  • Arcutis Clinical Site 52
  • Arcutis Clinical Site 63
  • Arcutis Clinical Site 65
  • Arcutis Clinical Site 31
  • Arcutis Clinical Site 24
  • Arcutis Clinical Site 62
  • Arcutis Clinical Site 39
  • Arcutis Clinical Site 08
  • Arcutis Clinical Site 27
  • Arcutis Clinical Site 74
  • Arcutis Clinical Site 66
  • Arcutis Clinical Site 61
  • Arcutis Clinical Site 04
  • Arcutis Clinical Site 02
  • Arcutis Clinical Site 18
  • Arcutis Clinical Site 03
  • Arcutis Clinical Site 06
  • Arcutis Clinical Site 76
  • Arcutis Clinical Site 25
  • Arcutis Clinical Site 29
  • Arcutis Clinical Site 64
  • Arcutis Clinical Site 73
  • Arcutis Clinical Site 36
  • Arcutis Clinical Site 78

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

ARQ-151 Cream 0.05%

ARQ-151 Vehicle Cream

Arm Description

Active comparator

Placebo comparator

Outcomes

Primary Outcome Measures

IGA Success, defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline at Week 4.
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).

Secondary Outcome Measures

In subjects with vIGA-AD score of 'Moderate' at randomization, IGA Success at Week 4
IGA Success, defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
In subjects with vIGA-AD score of 'Moderate' at randomization, achievement of at least 75% reduction in the Eczema Area and Severity Index (EASI-75) at Week 4
EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas.
In subjects with vIGA-AD score of 'Moderate' at randomization, vIGA-AD score of 'clear' or 'almost clear' at Week 4
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
vIGA-AD success at Week 2
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
vIGA-AD of 'clear' or 'almost 'clear' at Week 2
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
vIGA-AD success at Week 1
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
vIGA-AD of 'clear' or 'almost 'clear' at Week 1
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).

Full Information

First Posted
April 11, 2021
Last Updated
June 29, 2023
Sponsor
Arcutis Biotherapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04845620
Brief Title
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
Official Title
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects With Atopic Dermatitis
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
April 7, 2021 (Actual)
Primary Completion Date
June 1, 2023 (Actual)
Study Completion Date
June 1, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Arcutis Biotherapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).
Detailed Description
This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily for 4 weeks to subjects with atopic dermatitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atopic Dermatitis Eczema

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
652 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ARQ-151 Cream 0.05%
Arm Type
Experimental
Arm Description
Active comparator
Arm Title
ARQ-151 Vehicle Cream
Arm Type
Placebo Comparator
Arm Description
Placebo comparator
Intervention Type
Drug
Intervention Name(s)
ARQ-151 Active
Intervention Description
ARQ-151 Cream 0.05% - Active
Intervention Type
Drug
Intervention Name(s)
ARQ-151 Vehicle
Intervention Description
ARQ-151 Cream - Vehicle
Primary Outcome Measure Information:
Title
IGA Success, defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline at Week 4.
Description
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
Time Frame
Week 4
Secondary Outcome Measure Information:
Title
In subjects with vIGA-AD score of 'Moderate' at randomization, IGA Success at Week 4
Description
IGA Success, defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
Time Frame
Week 4
Title
In subjects with vIGA-AD score of 'Moderate' at randomization, achievement of at least 75% reduction in the Eczema Area and Severity Index (EASI-75) at Week 4
Description
EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas.
Time Frame
Week 4
Title
In subjects with vIGA-AD score of 'Moderate' at randomization, vIGA-AD score of 'clear' or 'almost clear' at Week 4
Description
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
Time Frame
Week 4
Title
vIGA-AD success at Week 2
Description
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
Time Frame
Week 2
Title
vIGA-AD of 'clear' or 'almost 'clear' at Week 2
Description
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
Time Frame
Week 2
Title
vIGA-AD success at Week 1
Description
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
Time Frame
Week 1
Title
vIGA-AD of 'clear' or 'almost 'clear' at Week 1
Description
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
Time Frame
Week 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed consent by parent(s) or legal guardian as required by local laws. Males and females, ages 2 to 5 years old at time of signing Informed Consent (Screening) and at Baseline (Day 1). Diagnosed with atopic dermatitis for at least 6 weeks, as determined by the Investigator. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening. In good health as judged by the Investigator. Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator. Exclusion Criteria: Subjects with any serious medical condition or clinically significant abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator Has unstable AD or any consistent requirement for high potency topical steroids. Subjects who are unwilling to refrain from prolonged sun exposure for 4 weeks prior to Baseline/Day 1 and during the study. Previous treatment with ARQ-151. Parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language(s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled (in other studies of ARQ-151) subjects living in the same house.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Berk, MD
Organizational Affiliation
Arcutis Biotherapeutics, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Arcutis Clinical Site 56
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
Arcutis Clinical Site 14
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35244
Country
United States
Facility Name
Arcutis Clinical Site 69
City
Montgomery
State/Province
Alabama
ZIP/Postal Code
36117
Country
United States
Facility Name
Arcutis Clinical Site 68
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Facility Name
Arcutis Clinical Site 26
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85255
Country
United States
Facility Name
Arcutis Clinical Site 50
City
Bryant
State/Province
Arkansas
ZIP/Postal Code
72022
Country
United States
Facility Name
Arcutis Clinical Site 59
City
Fort Smith
State/Province
Arkansas
ZIP/Postal Code
72916
Country
United States
Facility Name
Arcutis Clinical Site 71
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72212
Country
United States
Facility Name
Arcutis Clinical Site 09
City
Inglewood
State/Province
California
ZIP/Postal Code
90301
Country
United States
Facility Name
Arcutis Clinical Site 45
City
Rancho Santa Margarita
State/Province
California
ZIP/Postal Code
92688
Country
United States
Facility Name
Arcutis Clinical Site 30
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Arcutis Clinical Site 70
City
Thousand Oaks
State/Province
California
ZIP/Postal Code
91320
Country
United States
Facility Name
Arcutis Clinical Site 48
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Facility Name
Arcutis Clinical Site 33
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Facility Name
Arcutis Clinical Site 12
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33146
Country
United States
Facility Name
Arcutis Clinical Site 11
City
Delray Beach
State/Province
Florida
ZIP/Postal Code
33484
Country
United States
Facility Name
Arcutis Clinical Site 28
City
Largo
State/Province
Florida
ZIP/Postal Code
33770
Country
United States
Facility Name
Arcutis Clinical Site 10
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
Facility Name
Arcutis Clinical Site 79
City
Miami
State/Province
Florida
ZIP/Postal Code
33137
Country
United States
Facility Name
Arcutis Clinical Site 43
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
Facility Name
Arcutis Clinical Site 35
City
North Miami Beach
State/Province
Florida
ZIP/Postal Code
33162
Country
United States
Facility Name
Arcutis Clinical Site 75
City
Wellington
State/Province
Florida
ZIP/Postal Code
33449
Country
United States
Facility Name
Arcutis Clinical Site 20
City
Sandy Springs
State/Province
Georgia
ZIP/Postal Code
30328
Country
United States
Facility Name
Arcutis Clinical Site 82
City
Boise
State/Province
Idaho
ZIP/Postal Code
83706
Country
United States
Facility Name
Arcutis Clinical Site 60
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
Arcutis Clinical Site 07
City
Rolling Meadows
State/Province
Illinois
ZIP/Postal Code
33770
Country
United States
Facility Name
Arcutis Clinical Site 42
City
Clarksville
State/Province
Indiana
ZIP/Postal Code
47129
Country
United States
Facility Name
Arcutis Clinical Site 21
City
Plainfield
State/Province
Indiana
ZIP/Postal Code
46168
Country
United States
Facility Name
Arcutis Clinical Site 57
City
West Lafayette
State/Province
Indiana
ZIP/Postal Code
47906
Country
United States
Facility Name
Arcutis Clinical Site 22
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40217
Country
United States
Facility Name
Arcutis Clinical Site 46
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40241
Country
United States
Facility Name
Arcutis Clinical Site 84
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
Facility Name
Arcutis Clinical Site 34
City
Lake Charles
State/Province
Louisiana
ZIP/Postal Code
70605
Country
United States
Facility Name
Arcutis Clinical Site 51
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70005
Country
United States
Facility Name
Arcutis Clinical Site 40
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
Arcutis Clinical Site 77
City
Columbia
State/Province
Maryland
ZIP/Postal Code
21045
Country
United States
Facility Name
Arcutis Clinical Site 13
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20850
Country
United States
Facility Name
Arcutis Clinical Site 15
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20850
Country
United States
Facility Name
Arcutis Clinical Site 53
City
Auburn Hills
State/Province
Michigan
ZIP/Postal Code
48326
Country
United States
Facility Name
Arcutis Clinical Site 41
City
Bay City
State/Province
Michigan
ZIP/Postal Code
48706
Country
United States
Facility Name
Arcutis Clinical Site 36
City
Clarkston
State/Province
Michigan
ZIP/Postal Code
48346
Country
United States
Facility Name
Arcutis Clinical Site 72
City
Troy
State/Province
Michigan
ZIP/Postal Code
48084
Country
United States
Facility Name
Arcutis Clinical Site 05
City
New Brighton
State/Province
Minnesota
ZIP/Postal Code
55112
Country
United States
Facility Name
Arcutis Clinical Site 47
City
Saint Joseph
State/Province
Missouri
ZIP/Postal Code
64506
Country
United States
Facility Name
Arcutis Clinical Site 16
City
Reno
State/Province
Nevada
ZIP/Postal Code
89509
Country
United States
Facility Name
Arcutis Clinical Site 55
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03756
Country
United States
Facility Name
Arcutis Clinical Site 54
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11203
Country
United States
Facility Name
Arcutis Clinical Site 44
City
New York
State/Province
New York
ZIP/Postal Code
11415
Country
United States
Facility Name
Arcutis Clinical Site 32
City
Rochester
State/Province
New York
ZIP/Postal Code
14623
Country
United States
Facility Name
Arcutis Clinical Site 58
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Facility Name
Arcutis Clinical Site 81
City
Mason
State/Province
Ohio
ZIP/Postal Code
45040
Country
United States
Facility Name
Arcutis Clinical Site 01
City
Gresham
State/Province
Oregon
ZIP/Postal Code
97030
Country
United States
Facility Name
Arcutis Clinical Site 52
City
Portland
State/Province
Oregon
ZIP/Postal Code
97210
Country
United States
Facility Name
Arcutis Clinical Site 63
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Arcutis Clinical Site 65
City
Bethlehem
State/Province
Pennsylvania
ZIP/Postal Code
18105
Country
United States
Facility Name
Arcutis Clinical Site 31
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Facility Name
Arcutis Clinical Site 24
City
Newtown Square
State/Province
Pennsylvania
ZIP/Postal Code
19073
Country
United States
Facility Name
Arcutis Clinical Site 62
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Arcutis Clinical Site 39
City
Summerville
State/Province
South Carolina
ZIP/Postal Code
29486
Country
United States
Facility Name
Arcutis Clinical Site 08
City
Austin
State/Province
Texas
ZIP/Postal Code
78759
Country
United States
Facility Name
Arcutis Clinical Site 27
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401
Country
United States
Facility Name
Arcutis Clinical Site 74
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76244
Country
United States
Facility Name
Arcutis Clinical Site 66
City
Frisco
State/Province
Texas
ZIP/Postal Code
75034
Country
United States
Facility Name
Arcutis Clinical Site 61
City
Grapevine
State/Province
Texas
ZIP/Postal Code
76051
Country
United States
Facility Name
Arcutis Clinical Site 04
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Arcutis Clinical Site 02
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78213
Country
United States
Facility Name
Arcutis Clinical Site 18
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78218
Country
United States
Facility Name
Arcutis Clinical Site 03
City
South Jordan
State/Province
Utah
ZIP/Postal Code
84095
Country
United States
Facility Name
Arcutis Clinical Site 06
City
Burke
State/Province
Virginia
ZIP/Postal Code
22015
Country
United States
Facility Name
Arcutis Clinical Site 76
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22902
Country
United States
Facility Name
Arcutis Clinical Site 25
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202
Country
United States
Facility Name
Arcutis Clinical Site 29
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2J 7E1
Country
Canada
Facility Name
Arcutis Clinical Site 64
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3C 0N2
Country
Canada
Facility Name
Arcutis Clinical Site 73
City
Burlington
State/Province
Ontario
ZIP/Postal Code
L7L 6W6
Country
Canada
Facility Name
Arcutis Clinical Site 36
City
Markham
State/Province
Ontario
ZIP/Postal Code
L3P 1X3
Country
Canada
Facility Name
Arcutis Clinical Site 78
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7K 2C1
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

We'll reach out to this number within 24 hrs